| 摘要 |
Cannabidiol (CBD) for use in the treatment of focal seizures in Dravet Syndrome is provided. Preferably the focal seizures are focal seizures with impairment and the Dravet Syndrome is treatment-resistant. The CBD may be present as a highly purified extract of cannabis which comprises at least 98% (w/w) CBD, less than 0.15% THC and preferably up to 1% cannabidivarin (CBDV). The CBD may also be present as a synthetic compound. Preferably the CBD is for use in combination with one or more concomitant anti-epileptic drugs (AED) selected from the group consisting of carbamezapine, clobazam, clonazepam, clonidine, clorazepate, desmethylclobazam, diazepam, ethosuximide, felbamate, ketogenic diet, lacosamide, lamotrigine, levetiracetam, lorazepam, midazolam, N-desmethylclobazam, nordiazepam, oxycarbamezapine, perampanel, phenobarbital, phenytoin, pregabalin, rufinamide, stiripentol, topiramate, trazodone, vagus nerve stimulation, valproic acid, vigabatrin and zonisamide, where the number and/or dose of antiepileptic drugs that is/are used in combination with the CBD is reduced. A composition for use in the treatment of epilepsy characterised by focal seizures comprising cannabidiol (CBD), a solvent preferably sesame oil, a co-solvent preferably ethanol, a sweetener preferably sucralose and a flavouring is also provided. |
